Investors should consider Hims & Hers Health (HIMS) as a high-conviction play following reports of a major partnership with Novo Nordisk (NVO) or Eli Lilly (LLY) to provide branded weight loss medications. With short interest at 40% of the float, the stock could see a price jump of 40% to 60% in the immediate term, with analysts viewing the $22.00 to $30.00 range as still fundamentally "cheap." A formal partnership would likely re-accelerate revenue growth from 29% to over 45%, transforming HIMS from a compounded drug provider into a massive distribution platform for "Big Pharma." While Eli Lilly (LLY) is expected to dominate the market share for these drugs, HIMS captures immense value by using these high-demand treatments as a "flywheel" to cross-sell its other health services. Long-term investors should view current entry points as a value opportunity, though they must be prepared for extreme volatility and potential geopolitical market risks.

Hims & Hers Health, Inc. (HIMS)

The discussion centers on a potential major partnership announcement involving branded GLP-1 (weight loss) medications, likely involving Novo Nordisk or potentially Eli Lilly. The analyst addresses the validity of the news, the potential for a short squeeze, and the fundamental valuation of the company.

• News Authenticity: The analyst believes the reports of a partnership are likely true because they originated from Bloomberg and Danish news outlets. If the news were false, companies like Eli Lilly typically issue denials quickly.
• Short Interest & Squeeze Potential:
  • Approximately 40% of the float is short, which is significant but lower than historic squeezes like GameStop (130%).
  • The analyst predicts a potential price jump of 40% to 60% on Monday.
  • Despite the "squeeze" talk, the analyst does not believe it will reach the extreme levels of the 2008 Volkswagen squeeze.
• Business Model Context:
  • HIMS is a platform, not just a "GLP-1 company." Weight loss treatments represent only about 25% of the business.
  • The value lies in the flywheel effect: using high-demand products (like GLP-1s) to bring users onto the platform and then cross-selling other treatments (hair loss, ED, labs).
  • Even if margins on branded GLP-1s are low (referral fees), the customer acquisition value is "invaluable."
• Competitive Landscape:
  • The analyst expects the bulk of the GLP-1 business to eventually shift toward Eli Lilly (LLY).
  • There is speculation that HIMS could eventually partner with Lilly directly, which would be a massive catalyst for the stock.

Takeaways

• Valuation remains attractive: Even at $22.00 (after-hours price), the analyst considers the stock "very cheap." Even a jump to $25.00 or $30.00 would keep the stock in "cheap" territory based on the analyst's internal metrics.
• Growth Re-acceleration: If the partnership is confirmed, revenue growth could jump from the current guidance of 29% back up to 45%–55%.
• Risk Factors:
  • Macro/Geopolitical Events: The analyst warns of "dark gray" or "black swan" geopolitical events that could suppress the entire market regardless of company-specific news.
  • Bear Sentiment: Expect "bears" to downplay the news, arguing that HIMS won't make money on branded drugs or will lose their higher-margin "compounded" business.
• Investment Strategy: The analyst views the stock as a "steal" at $15 and still a strong value at $22, suggesting that for long-term believers in the platform model, the current entry points remain viable despite the recent price spike.

Eli Lilly (LLY) / Novo Nordisk (NVO)

• These major pharmaceutical companies are the primary providers of branded GLP-1 medications (Zepbound/Mounjaro and Wegovy/Ozempic).
• The analyst suggests that HIMS is moving toward a partnership model with these "Big Pharma" players rather than competing against them with compounded versions.

Takeaways

• Market Dominance: Eli Lilly is expected to capture the majority of the GLP-1 market share over the next six months.
• Partnership Potential: Any formal partnership between HIMS and Lilly is viewed as a "moonshot" scenario that would significantly re-rate the HIMS stock price upward.

Investment Themes: Telehealth & GLP-1 Flywheel

• The Platform Play: The core insight is that telehealth companies like HIMS should be valued as platforms (like a "recommender system") rather than single-product pharmacies.
• Customer Acquisition: High-demand weight loss drugs serve as a "top of funnel" marketing tool to acquire users who will eventually purchase other health services.
• Market Volatility: Investors should be prepared for extreme volatility on Monday mornings following major weekend news cycles, especially when high short interest is involved.